Charat Thongprayoon1, Wisit Kaewput2, Spencer T Hatch3, Tarun Bathini1, Konika Sharma1, Karn Wijarnpreecha1, Patompong Ungprasert4, Matthew D'Costa5, Michael A Mao5, Wisit Cheungpasitporn6. 1. Department of Internal Medicine, Bassett Medical Center, Cooperstown, NY, USA. 2. Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand. 3. Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, 2500 N. State St., Jackson, MS, 39216, USA. 4. Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. 5. Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA. 6. Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, 2500 N. State St., Jackson, MS, 39216, USA. wcheungpasitporn@gmail.com.
Abstract
BACKGROUND/ OBJECTIVES: We performed this systematic review and meta-analysis to evaluate effects of probiotics on inflammation, uremic toxins, and gastrointestinal (GI) symptoms in end-stage renal disease (ESRD) patients. METHODS: A literature search was conducted utilizing MEDLINE, EMBASE, and Cochrane Database from inception through October 2017. We included studies that assessed assessing effects of probiotics on inflammatory markers, protein-bound uremic toxins (PBUTs), and GI symptoms in ESRD patients on dialysis. Effect estimates from the individual study were extracted and combined utilizing random effect, generic inverse variance method of DerSimonian and Laird. The protocol for this meta-analysis is registered with PROSPERO; No. CRD42017082137. RESULTS: Seven clinical trials with 178 ESRD patients were enrolled. There was a significant reduction in serum C-reactive protein (CRP) from baseline to post-probiotic course (≥ 2 months after treatment) with standardized mean difference (SMD) of - 0.42 (95% CI - 0.68 to - 0.16, p = 0.002). When compared to control, patients who received probiotics also had a significant higher degree of reduction in CRP level with SMDs of - 0.37 (95% CI - 0.72 to 0.03, p = 0.04). However, there were no significant changes in serum TNF-alpha or albumin with SMDs of - 0.32 (95% CI - 0.92 to 0.28, p = 0.29) and 0.16 (95% CI - 0.20 to 0.53, p = 0.39), respectively. After probiotic course, there were also significant decrease in PBUTs and improvement in overall GI symptoms (reduction in GI symptom scores) with SMDs of - 0.61 (95% CI - 1.16 to - 0.07, p = 0.03) and - 1.04 (95% CI - 1.70 to - 0.38, p = 0.002), respectively. CONCLUSION: Our study demonstrates potential beneficial effects of probiotics on inflammation, uremic toxins, and GI Symptoms in ESRD patients. Future large-scale clinical studies are required to assess its benefits on other important clinical outcomes including patient mortality.
BACKGROUND/ OBJECTIVES: We performed this systematic review and meta-analysis to evaluate effects of probiotics on inflammation, uremic toxins, and gastrointestinal (GI) symptoms in end-stage renal disease (ESRD) patients. METHODS: A literature search was conducted utilizing MEDLINE, EMBASE, and Cochrane Database from inception through October 2017. We included studies that assessed assessing effects of probiotics on inflammatory markers, protein-bound uremic toxins (PBUTs), and GI symptoms in ESRDpatients on dialysis. Effect estimates from the individual study were extracted and combined utilizing random effect, generic inverse variance method of DerSimonian and Laird. The protocol for this meta-analysis is registered with PROSPERO; No. CRD42017082137. RESULTS: Seven clinical trials with 178 ESRDpatients were enrolled. There was a significant reduction in serum C-reactive protein (CRP) from baseline to post-probiotic course (≥ 2 months after treatment) with standardized mean difference (SMD) of - 0.42 (95% CI - 0.68 to - 0.16, p = 0.002). When compared to control, patients who received probiotics also had a significant higher degree of reduction in CRP level with SMDs of - 0.37 (95% CI - 0.72 to 0.03, p = 0.04). However, there were no significant changes in serum TNF-alpha or albumin with SMDs of - 0.32 (95% CI - 0.92 to 0.28, p = 0.29) and 0.16 (95% CI - 0.20 to 0.53, p = 0.39), respectively. After probiotic course, there were also significant decrease in PBUTs and improvement in overall GI symptoms (reduction in GI symptom scores) with SMDs of - 0.61 (95% CI - 1.16 to - 0.07, p = 0.03) and - 1.04 (95% CI - 1.70 to - 0.38, p = 0.002), respectively. CONCLUSION: Our study demonstrates potential beneficial effects of probiotics on inflammation, uremic toxins, and GI Symptoms in ESRDpatients. Future large-scale clinical studies are required to assess its benefits on other important clinical outcomes including patient mortality.
Authors: Natarajan Ranganathan; Pari Ranganathan; Eli A Friedman; Anthony Joseph; Barbara Delano; David S Goldfarb; Paul Tam; A Venketeshwer Rao; Emmanuel Anteyi; Carlos Guido Musso Journal: Adv Ther Date: 2010-08-16 Impact factor: 3.845
Authors: Diba Emal; Elena Rampanelli; Ingrid Stroo; Loes M Butter; Gwendoline J Teske; Nike Claessen; Geurt Stokman; Sandrine Florquin; Jaklien C Leemans; Mark C Dessing Journal: J Am Soc Nephrol Date: 2016-12-07 Impact factor: 10.121
Authors: Hans Strid; Magnus Simrén; Ann-Cathrine Johansson; Jan Svedlund; Ola Samuelsson; Einar S Björnsson Journal: Nephrol Dial Transplant Date: 2002-08 Impact factor: 5.992
Authors: Sandra Wagner; Thomas Merkling; Marie Metzger; Laetitia Koppe; Maurice Laville; Marie-Christine Boutron-Ruault; Luc Frimat; Christian Combe; Ziad A Massy; Bénédicte Stengel; Denis Fouque Journal: Front Nutr Date: 2022-03-30
Authors: Jana Holmar; Sofia de la Puente-Secades; Jürgen Floege; Heidi Noels; Joachim Jankowski; Setareh Orth-Alampour Journal: Cells Date: 2020-11-06 Impact factor: 6.600